Clinical Features of Untreated Type 2 Macular Telangiectasia and Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Macular Neovascularization

Müge Çoban Karataş Gürsel Yılmaz Aslıhan Yüce Sezen Çağla Sarıtürk

Published in: Turkish journal of ophthalmology (2022)

It is important to closely follow MacTel 2 patients for MNV development. To avoid adverse effects, we prefer to monitor patients who have not yet developed MNV. Patients with proliferative MacTel 2 with decreasing visual function may benefit from intravitreal anti-VEGF treatment.

Keyphrases

vascular endothelial growth factor
end stage renal disease
diabetic retinopathy
chronic kidney disease
endothelial cells
optical coherence tomography
mesenchymal stem cells
patient reported
replacement therapy